Antengene to Present Findings on Selinexor at ASH 2024
Antengene Corporation Limited, a biopharmaceutical leader committed to innovative medicine, is set to unveil crucial data from two late-stage clinical studies involving selinexor at the upcoming American Society of Hematology (ASH) Annual Meeting. Slated for December, this event in San Diego represents a significant opportunity for Antengene to showcase the promising results achieved with this pioneering treatment.
Details of the Presentations
The presentations will focus on groundbreaking findings related to two prominent studies of selinexor. The first poster highlights the efficacy of selinexor in combination with other treatments for patients facing relapsed and refractory multiple myeloma. This study, led by Dr. Jin Lu from Peking University People's Hospital, compares the response rates of different dosing schedules of selinexor in Chinese patients, promising to shed light on optimal treatment strategies.
Key Study Insights
The poster titled "Weekly Selinexor, Bortizomib, and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma: Primary Analysis of Phase III Bench Study" is expected to be presented during a session dedicated to pharmacological therapies, potentially influencing future clinical practices for this patient population.
Selinexor's Impact in Lymphoma Treatments
Another vital presentation will address the role of selinexor in treating relapsed or refractory extranodal NK/T-cell lymphoma. Conducted as a multicenter study, the preliminary findings of this research led by Dr. Rong Tao from Fudan University Shanghai Cancer Center will explore the efficacy of selinexor in conjunction with Tislelizumab.
Innovative Mechanism of Action
Selinexor, marketed under the brand name XPOVIO, operates through a unique mechanism that selectively inhibits the nuclear export protein XPO1. This inhibition allows tumor suppressor proteins to accumulate within cells, enhancing their antitumor effects. By reducing oncogenic protein levels, selinexor provides a multi-faceted approach to combatting various cancers.
The Future of Cancer Treatment with Selinexor
As Antengene leads the charge in advancing oncology therapeutics, they are running several clinical studies for XPOVIO throughout Asia, focusing on hematological malignancies and solid tumors. These studies are vital as they test selinexor's effectiveness in real-world scenarios.
Antengene’s Commitment to Oncology
Founded with the vision of "Treating Patients Beyond Borders," Antengene has developed a robust pipeline of nine oncology assets. Their continuous innovation and commitment to providing first-in-class and best-in-class treatments place them at the forefront of oncology research and patient care.
About Antengene Corporation Limited
Antengene Corporation Limited is widely recognized as a pioneering biopharmaceutical company focused on the discovery and development of innovative cancer treatments. With a strong emphasis on clinical research, Antengene seeks to bring forth therapeutics that can drastically change the landscape of cancer treatment.
Through a dedication to research and development, the company has successfully earned numerous investigational drug approvals, positioning itself as a leader in the Asian biopharmaceutical market.
Frequently Asked Questions
What is the focus of Antengene's research?
Antengene's research is primarily focused on developing innovative therapies for hematologic malignancies and solid tumors.
What is XPOVIO?
XPOVIO (selinexor) is the first oral selective inhibitor of the nuclear export protein XPO1, recognized for its unique mechanism in fighting cancer.
How is selinexor administered?
Selinexor is administered orally, making it a convenient option for patients compared to traditional chemotherapy methods.
What types of cancer can XPOVIO treat?
XPOVIO has shown efficacy in treating various cancers, including multiple myeloma and extranodal NK/T-cell lymphoma.
How does selinexor work?
Selinexor works by blocking a protein that allows cancer cells to survive, promoting the accumulation of tumor suppressor proteins and reducing oncogenic proteins.
